Improving pharmaceutical facility design with Chips, generative design and automation.

It needs to sit across the entire operation.We are interested in increasing quality, productivity, timeliness and cost effectiveness.

So we have to ask certain key questions from the outset, like: what’s the least amount of material that could possibly be used to build an asset?What’s the smallest number of times that asset could be touched or processed by people?How productive can those people be?.

Our goal with P-DfMA is lean construction.We want to remove anything which doesn’t add value.

To achieve the best possible results, we must change the way we think, the way we manage materials and people.

Design must form the entry point, with that particular element of P-DfMA serving as the foundation and pervading principle for everything which follows.If a new, highly energy-efficient product creates local jobs, then we’ll need a clear route to market for that product, as well as a value-based decision about how it’s deployed.

At the moment, however, this isn’t really possible, because we don’t have a clear set of rules.We have too many non-interoperable systems and ecosystems.

Our current decisions are based on cost, rather than value and outcomes.Initial capital costs and whole-life costs will always be important, but all of the various value metrics and value drivers need to be considered alongside them..